Chronic Hepatitis B: Epidemiology, Prevention and Risk Stratification
Nov
2026
Description
This session covers the changing epidemiology of chronic hepatitis B, including HCC risk stratification, vaccine-derived immunity trends, screening in high-burden settings, and refugee population data.
Presentations
8:00 AM
- 8:15 AM
Convention Center - Bluebird Ballroom 1C
Hepatitis B Virus Prevalence Among US-Bound Refugees, 2018–2023
Erin M Mann, PhD, MPH | Abstract Presenter
8:15 AM
- 8:30 AM
Convention Center - Bluebird Ballroom 1C
Liver stiffness predicts HCC in non-cirrhotic HBeAg negative patients who do not meet treatment criteria based on HBV DNA and ALT – results from the global RADICAL consortium
Lisa V van Velsen, MD | Abstract Presenter
8:30 AM
- 8:45 AM
Convention Center - Bluebird Ballroom 1C
Integrating Hepatitis B Screening into Primary Care in a High-Burden LMIC: A Mixed-Methods Implementation Study from Viet Na
Thanh V Kim | Abstract Presenter
8:45 AM
- 9:00 AM
Convention Center - Bluebird Ballroom 1C
Distribution of Natural History Stages in Children Aged 1–12 Years With Chronic Hepatitis B Virus Infection: A Real-World Multicenter Retrospective Study
Qing-Lei Zeng | Abstract Presenter
9:00 AM
- 9:15 AM
Convention Center - Bluebird Ballroom 1C
"Metabolic Hepatitis B" (Met-B): A Distinct Clinical Phenotype carries a higher risk of Hepatocellular Carcinoma development Despite Effective Antiviral Therapy - A Large histology based Longitudinal Cohort Study.
Phool Chand, MD, DM | Abstract Presenter
9:15 AM
- 9:30 AM
Convention Center - Bluebird Ballroom 1C
Generational Shifts in U.S. Hepatitis B Vaccine-Derived Immunity After Universal Infant Vaccination
Giovanni A Roldan, MD | Abstract Presenter
